CHARGED ALPHA
Stock Analysis
Stock Library / TECH
TECH Technology Latest YouTube: Q3 FY2026

TECH

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

TECH Stock: Revenue Misses by 1% — Q3 FY2026

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q3 FY2026
Podcast available
Yes
Current price
$70.96
+0.58 (+0.82%)
Trailing / Forward P/E
101.37x
Forward: 34.69x
Market cap / Volume
Volume:
Revenue / Earnings Growth
-1.5%
Earnings: 128.6%
Margins
25.2% op
Gross: 66.4% · Net: 9.0%
Balance sheet
4.49x current
Debt / Equity: 13.9
52-week range / Beta
$43.20 - $72.16
Beta: 1.29
Analyst target
$69.08
Upside: -2.6%
Cash / shareholder return
2.71% FCF yield
Dividend yield: 0.45%

Company context

Industry: Biotechnology
Country: United States
Employees:
Price to book: 5.33x
Return on equity: 5.3%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Price chart

Market context for TECH

Competitive view

TECH vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

TECH latest YouTube video thumbnail YouTube
TECH
TECH
Latest video
Q3 FY2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intel Corporation latest YouTube video thumbnail YouTube
Intel Corporation
INTC
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.
Salesforce latest YouTube video thumbnail YouTube
Salesforce
CRM
Latest video
Q1 FY2027
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
TECH
$11.06B
TECH
INTC
$554.07B
Intel Corporation
CRM
$136.43B
Salesforce
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
TECH
101.4x
TECH
INTC
Intel Corporation
CRM
19.3x
Salesforce
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
TECH
34.7x
TECH
INTC
70.6x
Intel Corporation
CRM
10.7x
Salesforce
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
TECH
-1.5%
TECH
INTC
7.2%
Intel Corporation
CRM
13.3%
Salesforce
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
TECH
128.6%
TECH
INTC
Intel Corporation
CRM
52.2%
Salesforce
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
TECH
25.2%
TECH
INTC
6.9%
Intel Corporation
CRM
21.8%
Salesforce
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
TECH
66.4%
TECH
INTC
37.2%
Intel Corporation
CRM
77.6%
Salesforce
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
TECH
9.0%
TECH
INTC
-5.9%
Intel Corporation
CRM
18.7%
Salesforce
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
TECH
5.3%
TECH
INTC
-2.9%
Intel Corporation
CRM
16.9%
Salesforce
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
TECH
2.7%
TECH
INTC
-1.5%
Intel Corporation
CRM
12.1%
Salesforce
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
TECH
13.92x
TECH
INTC
36.03x
Intel Corporation
CRM
124.28x
Salesforce
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
TECH
4.49x
TECH
INTC
2.31x
Intel Corporation
CRM
0.79x
Salesforce
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
TECH
1.29
TECH
INTC
2.19
Intel Corporation
CRM
1.18
Salesforce
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
TECH
0.5%
TECH
INTC
Intel Corporation
CRM
1.0%
Salesforce
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
TECH
-2.6%
TECH
INTC
-8.5%
Intel Corporation
CRM
47.9%
Salesforce

Episode timeline

Episode archive for TECH

Each row is one earnings episode with every verified platform link available.

Q3 FY2026
Episode live
Published youtube podcast complete
TECH Stock: Revenue Misses by 1% — Q3 FY2026
Quarterly earnings-analysis entry for TECH. Use the links on the right to open the video or podcast episode.